Search research articles
Contact Us
Filters
Showing results (151-160 of 274) with videos related to
Page
of 28
Sort By:
American Journal of Hematology
|
August 28, 2023
Ongoing symptoms following complete surgical excision in unicentric Castleman disease
Mateo Sarmiento Bustamante, Saishravan Shyamsundar, Freda R Coren, et al.
Current Problems in Cancer. Case Reports
|
March 16, 2026
Breast-implant associated unicentric castleman disease: a case report
Saishravan Shyamsundar, Mateo Sarmiento Bustamante, Larissa Borys, et al.
Haematologica
|
May 30, 2013
Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma
Xenofon Papanikolaou, Jackie Szymonifka, Adam Rosenthal, et al.
Blood Advances
|
July 1, 2025
Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging
Carolina Schinke, Leo Rasche, Cody Ashby, et al.
American Journal of Hematology
|
June 20, 2025
International Consensus Histopathological Criteria for Subtyping Idiopathic Multicentric Castleman Disease Based on Machine Learning Analysis
Midori Filiz Nishimura, Tomoka Haratake, Yoshito Nishimura, et al.
European Journal of Haematology
|
October 27, 2020
Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA
Shayu Deshpande, Ruslana G Tytarenko, Yan Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 14, 2010
High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2
Yiming Zhou, Lijuan Chen, Bart Barlogie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 7, 2007
Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling
Jeffrey Haessler, John D Shaughnessy, Fenghuang Zhan, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 31, 2013
Patterns of central nervous system involvement in relapsed and refractory multiple myeloma
Al-ola Abdallah, Shebli Atrash, Zainab Shahid, et al.
Haematologica
|
May 5, 2025
<i>Erratum</i> to: Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease
Mateo Sarmiento Bustamante, Sheila K Pierson, Yue Ren, et al.
Page
of 28
Search research articles
Search
Showing results (151-160 of 274) with videos related to
Sort By:
Page
of 28
American Journal of Hematology
|
August 28, 2023
Ongoing symptoms following complete surgical excision in unicentric Castleman disease
Mateo Sarmiento Bustamante, Saishravan Shyamsundar, Freda R Coren, et al.
Current Problems in Cancer. Case Reports
|
March 16, 2026
Breast-implant associated unicentric castleman disease: a case report
Saishravan Shyamsundar, Mateo Sarmiento Bustamante, Larissa Borys, et al.
Haematologica
|
May 30, 2013
Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma
Xenofon Papanikolaou, Jackie Szymonifka, Adam Rosenthal, et al.
Blood Advances
|
July 1, 2025
Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging
Carolina Schinke, Leo Rasche, Cody Ashby, et al.
American Journal of Hematology
|
June 20, 2025
International Consensus Histopathological Criteria for Subtyping Idiopathic Multicentric Castleman Disease Based on Machine Learning Analysis
Midori Filiz Nishimura, Tomoka Haratake, Yoshito Nishimura, et al.
European Journal of Haematology
|
October 27, 2020
Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA
Shayu Deshpande, Ruslana G Tytarenko, Yan Wang, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
April 14, 2010
High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2
Yiming Zhou, Lijuan Chen, Bart Barlogie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 7, 2007
Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling
Jeffrey Haessler, John D Shaughnessy, Fenghuang Zhan, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 31, 2013
Patterns of central nervous system involvement in relapsed and refractory multiple myeloma
Al-ola Abdallah, Shebli Atrash, Zainab Shahid, et al.
Haematologica
|
May 5, 2025
<i>Erratum</i> to: Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease
Mateo Sarmiento Bustamante, Sheila K Pierson, Yue Ren, et al.
Page
of 28